Basketter David A, Clapp Catherine, Jefferies Donna, Safford Bob, Ryan Cindy A, Gerberick Frank, Dearman Rebecca J, Kimber Ian
Unilever, Colworth House, Sharnbrook, Bedfordshire, UK.
Contact Dermatitis. 2005 Nov;53(5):260-7. doi: 10.1111/j.0105-1873.2005.00707.x.
For years, methods have been available for the predictive identification of chemicals that possess the intrinsic potential to cause skin sensitization. However, many have proven less suitable for the determination of relative sensitizing potency. In this respect, the local lymph node assay (LLNA) has been shown to have a number of important advantages. Through interpolation of LLNA dose-response data, the concentration of a chemical required to produce a threshold positive response (a 3-fold increase in activity compared with concurrent vehicle controls, the EC3 value) can be measured. The robustness of this parameter has been demonstrated rigorously in terms of inter- and intralaboratory reproducibility. Additionally, the relationship between potency estimates from the LLNA and an appreciation of human potency based on clinical experience has been reported previously. In the present investigations, we have sought to consolidate further our understanding of the association between EC3 values and human skin-sensitization potency by undertaking a thorough and extensive analysis of existing human predictive assays, particularly where dose-response information is available, from historical human repeated insult patch tests (HRIPTs). From these human data, information on the approximate threshold for the induction of skin sensitization in the HRIPT was determined for 26 skin-sensitizing chemicals. These data were then compared with LLNA-derived EC3 values. The results from each assay, expressed as dose per unit area (microg/cm(2)), revealed a clear linear relationship between the 2 values, thereby substantiating further the utility of LLNA EC3 values for prediction of the relative human sensitizing potency of newly identified skin sensitizers.
多年来,一直存在用于预测性鉴定具有引起皮肤致敏内在潜力的化学物质的方法。然而,许多方法已被证明不太适合用于确定相对致敏强度。在这方面,局部淋巴结试验(LLNA)已显示出许多重要优势。通过对LLNA剂量反应数据进行内插,可以测量产生阈值阳性反应(与同时进行的赋形剂对照相比活性增加3倍,即EC3值)所需的化学物质浓度。该参数的稳健性已在实验室间和实验室内再现性方面得到了严格证明。此外,先前已报道了LLNA的效力估计值与基于临床经验对人体效力的认识之间的关系。在本研究中,我们试图通过对现有的人体预测性试验进行全面而广泛的分析,特别是在有剂量反应信息的情况下,从历史人体重复刺激斑贴试验(HRIPT)中进一步巩固我们对EC3值与人体皮肤致敏效力之间关联的理解。从这些人体数据中,确定了26种皮肤致敏化学物质在HRIPT中诱导皮肤致敏的近似阈值信息。然后将这些数据与LLNA衍生的EC3值进行比较。每种试验的结果以每单位面积剂量(微克/平方厘米)表示,揭示了这两个值之间存在明显的线性关系,从而进一步证实了LLNA EC3值在预测新鉴定的皮肤致敏剂相对人体致敏效力方面的实用性。